Zentalis Pharmaceuticals (ZNTL) EBT (2019 - 2026)

Zentalis Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$35.2 million for Q1 2026.

• On a quarterly basis, EBT rose 27.02% year-over-year to -$35.2 million in Q1 2026; TTM through Mar 2026 was -$123.6 million, a 44.87% increase from a year earlier, with the FY2025 full-year figure at -$136.6 million, up 17.55% from the prior year.
• EBT slipped to -$35.2 million in Q1 2026 per ZNTL's latest filing, from -$34.8 million in the prior quarter.
• Across five years, EBT topped out at $10.2 million in Q1 2024 and bottomed at -$99.5 million in Q2 2023.
• The 5-year median for EBT is -$48.5 million (2022), against an average of -$49.2 million.
• Across the five-year window, EBT surged 116.74% in 2024 and slumped 574.11% in 2025, its largest moves.
• Year by year, EBT stood at -$48.5 million in 2022, then fell by 25.87% to -$61.1 million in 2023, then grew by 21.94% to -$47.7 million in 2024, then advanced by 27.06% to -$34.8 million in 2025, then declined by 1.32% to -$35.2 million in 2026.
• Per Business Quant, the three latest ZNTL EBT figures stand at -$35.2 million (Q1 2026), -$34.8 million (Q4 2025), and -$26.7 million (Q3 2025).